Verve Therapeutics retains CFO and COO with $499K and $416K bonuses tied to Lilly merger

Verve Therapeutics, Inc.

CFO Allison Dorval receives retention award of $499,200; COO/GC Andrew Ashe receives $416,000.
Awards payable on 12-month anniversary of merger closing, subject to continued employment.
Upon termination without cause after closing, Ashe gets 100% unpaid; Dorval gets 50% immediately, 50% later.
Program aims to retain key executives through Eli Lilly acquisition (pending).

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.